In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dynogen Pharmaceuticals, Inc.

Latest From Dynogen Pharmaceuticals, Inc.

Two Chinese IPOs Kickstart A Hectic Biotech Fundraising Season

Two IPOs and 12 venture capital and private equity deals in China raised a combined $1bn in a hectic few weeks of October.

China Financing

A Peek At The Hand Of Cell, Gene And RNA Therapies

With nearly 3,500 therapies in development globally, and almost $480m in start-up financing in Q1 of 2021 alone, the cell, gene and RNA therapy area is seeing a sharp rise in development and attention. 

Clinical Trials Commercial

Astellas calls time on ex-Dynogen US facility as it tidies R&D network

Astellas is to close down a small research subsidiary in the US by the end of this year, as it looks to control costs and rationalise its corporate R&D effort.

Gynecology & Urology Japan

Biotechs Target the GI Tract

Regulatory risk and a mature market for some indications have driven Big Pharma players from the gastrointestinal space. That signals possible biotech opportunity. In this issue, we profile Alvine Pharmaceuticals, Genetic Analysis, Meritage Pharma and Ventrus Biosciences.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register